Osthole, a potential antidiabetic agent, alleviates hyperglycemia in db/db mice

Chemico-Biological Interactions

Volumn 181, Issue 3, 2009, Pages 309-315

  Liang, Hong Jen ^a   Suk, Fat Moon ^b   Wang, Chung Kwe ^b,c   Hung, Ling Fang ^d   Liu, Der Zen ^e   Chen, Nai Qi ^d   Chen, Yu Chien ^d   Chang, Chun Chao ^b   Liang, Yu Chih ^b,d  

^a YUANPEI UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c TAIPEI CITY HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

AMPK; Diabetic db db mice; Glucose; Osthole; Peroxisome proliferator activated receptor

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYL COENZYME A CARBOXYLASE; ANTIDIABETIC AGENT; CARNITINE PALMITOYLTRANSFERASE I; FATTY ACID BINDING PROTEIN 2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; INSULIN SENSITIZING AGENT; LIPID; LONG CHAIN FATTY ACID COENZYME A LIGASE; OSTHOLE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TROGLITAZONE;

ANGELICA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CNIDIUM; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ACTIVITY; DRUG DETERMINATION; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IN VITRO STUDY; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; METABOLIC SYNDROME X; MOUSE; MOUSE STRAIN; NONHUMAN;

3T3-L1 CELLS; ACETYL-COA CARBOXYLASE; ADENYLATE KINASE; ADIPOCYTES; ANIMALS; BASE SEQUENCE; CELL DIFFERENTIATION; COUMARINS; DNA PRIMERS; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MICE; MICE, INBRED C57BL; PHOSPHORYLATION; PPAR ALPHA; PPAR GAMMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

ANGELICA PUBESCENS; ANIMALIA; CNIDIUM MONNIERI; MUS;

EID: 70249109667     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2009.08.003     Document Type: Article

References (43)

1. The Pharmacopoeia Commission of PRC. The Pharmacopoeia of the People's Republic of China. Part I (2000), Chemical Industry Publishing House, Beijing, China p. 256
2. You L., Feng S., An R., and Wang X. Osthole: a promising lead compound for drug discovery from a traditional Chinese medicine (TCM). Nat. Prod. Commun. 4 (2009) 297-302
3. Li X.X., Hara I., and Matsumiya T. Effects of osthole on postmenopausal osteoporosis using ovariectomized rats; comparison to the effects of estradiol. Biol. Pharm. Bull. 25 (2002) 738-742
4. Kuo P.L., Hsu Y.L., Chang C.H., and Chang J.K. Osthole-mediated cell differentiation through bone morphogenetic protein-2/p38 and extracellular signal-regulated kinase 1/2 pathway in human osteoblast cells. J. Pharmacol. Exp. Ther. 314 (2005) 1290-1299
5. Zhang Q., Qin L., He W., Van Puyvelde L., Maes D., Adams A., Zheng H., and De Kimpe N. Coumarins from Cnidium monnieri and their antiosteoporotic activity. Planta Med. 73 (2007) 13-19
6. Huang R.L., Chen C.C., Huang Y.L., Hsieh D.J., Hu C.P., Chen C.F., and Chang C. Osthole increases glycosylation of hepatitis B surface antigen and suppresses the secretion of hepatitis B virus in vitro. Hepatology 24 (1996) 508-515
7. Okamoto T., Kawasaki T., and Hino O. Osthole prevents anti-Fas antibody-induced hepatitis in mice by affecting the caspase-3-mediated apoptotic pathway. Biochem. Pharmacol. 65 (2003) 677-681
8. Okamoto T., Kobayashi T., and Yoshida S. Synthetic derivatives of osthole for the prevention of hepatitis. Med. Chem. 3 (2007) 35-44
9. Matsuda H., Tomohiro N., Ido Y., and Kubo M. Anti-allergic effects of cnidii monnieri fructus (dried fruits of Cnidium monnieri) and its major component, osthol. Biol. Pharm. Bull. 25 (2002) 809-812
10. Chiu P.R., Lee W.T., Chu Y.T., Lee M.S., Jong Y.J., and Hung C.H. Effect of the Chinese herb extract osthol on IL-4-induced eotaxin expression in BEAS-2B cells. Pediatr. Neonatol. 49 (2008) 135-140
11. Luszczki J.J., Andres-Mach M., Cisowski W., Mazol I., Glowniak K., and Czuczwar S.J. Osthole suppresses seizures in the mouse maximal electroshock seizure model. Eur. J. Pharmacol. 607 (2009) 107-109
12. Guh J.H., Yu S.M., Ko F.N., Wu T.S., and Teng C.M. Antiproliferative effect in rat vascular smooth muscle cells by osthole, isolated from Angelica pubescens. Eur. J. Pharmacol. 298 (1996) 191-197
13. Chou S.Y., Hsu C.S., Wang K.T., Wang M.C., and Wang C.C. Antitumor effects of Osthol from Cnidium monnieri: an in vitro and in vivo study. Phytother. Res. 21 (2007) 226-230
14. Ogawa H., Sasai N., Kamisako T., and Baba K. Effects of osthole on blood pressure and lipid metabolism in stroke-prone spontaneously hypertensive rats. J. Ethnopharmacol. 112 (2007) 26-31
15. Zhang Y., Xie M., Xue J., and Gu Z. Osthole improves fat milk-induced fatty liver in rats: modulation of hepatic PPAR-alpha/gamma-mediated lipogenic gene expression. Planta Med. 73 (2007) 718-724
16. Zhang Y., Xie M.L., Zhu L.J., and Gu Z.L. Therapeutic effect of osthole on hyperlipidemic fatty liver in rats. Acta Pharmacol. Sin. 28 (2007) 398-403
17. Zhang Y., Xie M.L., Xue J., and Gu Z.L. Osthole regulates enzyme protein expression of CYP7A1 and DGAT2 via activation of PPARalpha/gamma in fat milk-induced fatty liver rats. J. Asian Nat. Prod. Res. 10 (2008) 807-812
18. Sun F., Xie M.L., Zhu L.J., Xue J., and Gu Z.L. Inhibitory effect of osthole on alcohol-induced fatty liver in mice. Dig. Liver Dis. 41 (2009) 127-133
19. Langley A.K., Suffoletta T.J., and Jennings H.R. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus. Pharmacotherapy 27 (2007) 1163-1180
20. Schimmack G., Defronzo R.A., and Musi N. AMP-activated protein kinase: role in metabolism and therapeutic implications. Diabetes Obes. Metab. 8 (2006) 591-602
21. Lage R., Diéguez C., Vidal-Puig A., and López M. AMPK: a metabolic gauge regulating whole-body energy homeostasis. Trends Mol. Med. 14 (2008) 539-549
22. Hutchinson D.S., Summers R.J., and Bengtsson T. Regulation of AMP-activated protein kinase activity by G-protein coupled receptors: potential utility in treatment of diabetes and heart disease. Pharmacol. Ther. 119 (2008) 291-310
23. Schmidt A., Endo N., Rutledge S.J., Vogel R., Shinar D., and Rodan G.A. Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol. Endocrinol. 6 (1992) 1634-1641
24. Suk F.M., Lin S.Y., Chen C.H., Yen S.J., Su C.H., Liu D.Z., Hou W.C., Hung L.F., Lin P.J., and Liang Y.C. Taiwanofungus camphoratus activates peroxisome proliferator-activated receptors and induces hypotriglyceride in hypercholesterolemic rats. Biosci. Biotechnol. Biochem. 72 (2008) 1704-1713
25. Liu D.Z., Liang H.J., Chen C.H., Lin S.Y., Zhong W.B., Ho F.M., Hou W.C., Lo J.L., Ho Y.S., Lin P.J., Hung L.F., and Liang Y.C. Switch activation of PI-PLC downstream signals in activated macrophages with wortmannin. Biochim. Biophys. Acta 1773 (2007) 869-879
26. Ricote M., Li A.C., Willson T.M., Kelly C.J., and Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391 (1998) 79-82
27. Tontonoz P., and Spiegelman B.M. Fat and beyond: the diverse biology of PPARgamma. Annu. Rev. Biochem. 77 (2008) 289-312
28. Sher T., Yi H.F., McBride O.W., and Gonzalez F.J. cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry 32 (1993) 5598-5604
29. Bragt M.C., and Popeijusm H.E. Peroxisome proliferator-activated receptors and the metabolic syndrome. Physiol. Behav. 94 (2008) 187-197
30. Neve B.P., Fruchart J.C., and Staels B. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem. Pharmacol. 60 (2000) 1245-1250
31. Jay M.A., and Ren J. Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus. Curr. Diabetes Rev. 3 (2007) 33-39
32. Nesto R.W., Bell D., Bonow R.O., Fonseca V., Grundy S.M., Horton E.S., Le Winter M., Porte D., Semenkovich C.F., Smith S., Young L.H., and Kahn R. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 27 (2004) 256-263
33. Nissen S.E., Wolski K., and Topol E.J. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. J. Am. Med. Assoc. 294 (2005) 2581-2586
34. Chang F., Jaber L.A., Berlie H.D., and O'Connell M.B. Evolution of peroxisome proliferator-activated receptor agonists. Ann. Pharmacother. 41 (2007) 973-983
35. Allen T., Zhang F., Moodie S.A., Clemens L.E., Smith A., Gregoire F., Bell A., Muscat G.E., and Gustafson T.A. Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity. Diabetes 55 (2006) 2523-2533
36. Burgermeister E., Schnoebelen A., Flament A., Benz J., Stihle M., Gsell B., Rufer A., Ruf A., Kuhn B., Märki H.P., Mizrahi J., Sebokova E., Niesor E., and Meyer M. A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro. Mol. Endocrinol. 20 (2006) 809-830
37. Han K.L., Jung M.H., Sohn J.H., and Hwang J.K. Ginsenoside 20S-protopanaxatriol (PPT) activates peroxisome proliferator-activated receptor gamma (PPARgamma) in 3T3-L1 adipocytes. Biol. Pharm. Bull. 29 (2006) 110-113
38. Harinantenaina L., Tanaka M., Takaoka S., Oda M., Mogami O., Uchida M., and Asakawa Y. Momordica charantia constituents and antidiabetic screening of the isolated major compounds. Chem. Pharm. Bull. (Tokyo) 54 (2006) 1017-1021
39. Krawinkel M.B., and Keding G.B. Bitter gourd (Momordica Charantia): a dietary approach to hyperglycemia. Nutr. Rev. 64 (2006) 331-337
40. Burns K.A., and Vanden Heuvel J.P. Modulation of PPAR activity via phosphorylation. Biochim. Biophys. Acta 1771 (2007) 952-960
41. Leff T. AMP-activated protein kinase regulates gene expression by direct phosphorylation of nuclear proteins. Biochem. Soc. Trans. 31 (2003) 224-227
42. Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., Wu M., Ventre J., Doebber T., Fujii N., Musi N., Hirshman M.F., Goodyear L.J., and Moller D.E. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108 (2001) 1167-1174
43. Song F., Xie M.L., Zhu L.J., Zhang K.P., Xue J., and Gu Z.L. Experimental study of osthole on treatment of hyperlipidemic and alcoholic fatty liver in animals. World J. Gastroenterol. 12 (2006) 4359-4363